Combo Treatment of HCC

liver411

Oncol Rep. 2004 Jan;11(1):105-9. Combination therapy with radiofrequency ablation and transcatheter chemoembolization for the treatment of hepatocellular carcinoma: Short-term recurrences and survival. Yamakado K, Nakatsuka A, Akeboshi M, Shiraki K, Nakano T, Takeda K. Department of Radiology, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8067, Japan. [email protected] To evaluate short-term clinical results of radiofrequency (RF) ablation combined with transcatheter chemoembolization for the treatment of hepatocellular carcinoma (HCC) and to identify factors having influence on early intrahepatic recurrence. Sixty-four patients with 92 HCC lesions underwent RF ablation within 2 weeks after chemoembolization. The maximum tumor size was small (5 cm) were significantly linked with higher probability of early intrahepatic recurrence. In the multivariate analysis, tumor number was the only independent factor having significant impact on early intrahepatic recurrence. The estimated 1- and 2-year survival rates were 100% and 93%, respectively. This combined therapy showed good early therapeutic effects on treated lesions and survival. Tumor number and maximum tumor size are important factors for early intrahepatic recurrence. PMID: 14654911 [PubMed - in process]